Dr K Baraneedharan, Senior Consultant in Diabetology and General Medicine, highlights that dapagliflozin sitagliptin FDC offers complementary, beta-cell independent glucose control in T2DM. Indian data show improved HbA1c, BP, and lipids with added cardiorenal benefits. Supported by recent guidelines, early combination therapy may help achieve durable glycemic control in high-risk patients.